Back

Predictors of inappropriate dosing of direct oral anticoagulants in nonagenarian patients with atrial fibrillation.

27 August 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Pharmacology and pharmacotherapy e-posters Cardiovascular Pharmacotherapy ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Mr Pablo Dominguez Erquicia

Hospital Universitario Alvaro Cunqueiro, Vigo (Spain)

57 More presentations in this session

Presentation thumbnail
Efficacy of propafenone vs. amiodarone in pharmacological cardioversion of recent-onset atrial fibrillation to sinus rhythm: a pooled meta-analysis of 9 randomized controlled trials
Doctor J. Borovac (Split, HR)
Abstract Slides
Presentation thumbnail
The prevalence and safety of direct oral anticoagulants in patients with non-atrial fibrillation associated intra-cardiac thrombus
Doctor A. KANWAL (Valhalla, US)
Abstract Slides
Presentation thumbnail
Efficiency and safety of the modified protocol for cardioversion of atrial fibrillation using the antiarrhythmic drug niferidil. First results of clinical use.
Doctor K. Dzaurova (Moscow, RU)
Abstract Slides
Presentation thumbnail
The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a meta-analysis
Mrs A. Boulmpou (Nijmegen, NL)
Abstract Slides
Presentation thumbnail
Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis
Mrs A. Boulmpou (Nijmegen, NL)
Abstract Slides

Access the full session

Session thumbnail
Pharmacology and pharmacotherapy e-posters

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Congress Presentation
State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources